Computer Sciences Corporation acquires full interest in DynPort Vaccine Company LLC (DVC)
Computer Sciences Corporation announced that it has acquired Porton International Inc.’s interest in DynPort Vaccine Company LLC (DVC), a biopharmaceutical company focused on the development of biodefense biologics products. Terms of the agreement were not disclosed.
Formerly a joint venture between CSC and Porton International Inc., DVC has been the prime systems contractor for the Department of Defense Joint Vaccine Acquisition Program since 1997.
Products in development at DVC include vaccines for botulinum neurotoxin, tularemia, Venezuelan equine encephalitis, anthrax and plague, and a therapeutic blood product, vaccinia immune globulin, to treat complications of smallpox vaccination.
DVC is dedicated to the development and licensure of safe and efficacious biodefense vaccines for the Department of Defense and civilian populations. DVC is part of CSC’s Enforcement, Security and Intelligence organization, which CSC created in 2002 to support programs enhancing U.S. security.
Founded in 1959, Computer Sciences Corporation is a leading global information technology (IT) services company. CSC’s mission is to provide customers in industry and government with solutions crafted to meet their specific challenges and enable them to profit from the advanced use of technology.
With approximately 90,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC’s own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in El Segundo, Calif., CSC reported revenue of $14.9 billion for the 12 months ended July 2, 2004. For more information, visit the company’s Web site at www.csc.com .
